News & Updates

2610, 2017

New Study Published in JAMA Oncology Shows MammaPrint Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay

October 26th, 2017|

Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay’s intermediate range Physicians changed their treatment decisions in approximately 34% of all cases and in 76% Read More

1309, 2017

10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment

September 13th, 2017|

First time 10-year prospective outcome data confirms clinical utility of MammaPrint for lymph node-negative and lymph node-positive patients MINDACT sub-study shows that even tumors less than 1cm in size can be aggressive with 24% reclassified Read More